The characteristics of the stone and urine composition in Chinese stone formers: primary report of a single-center results.

Urology (2014-02-04)
Wenqi Wu, Dong Yang, Hans-Göran Tiselius, Lili Ou, Yeping Liang, Hanliang Zhu, Shujue Li, Guohua Zeng
RESUMEN

To assess urine composition in Chinese patients with urolithiasis. Five hundred seven Chinese patients with urolithiasis from our center in southern China were included in this study. Analysis of stone composition was performed using infrared spectrometry. From all patients, 24-hour urine samples were collected for analysis of urinary variables. Some ion activity product risk indices were also calculated. The major stone constituents in the 507 analyzed stones were as follows: calcium oxalate (78.3%), infection stone components (14.6%), uric acid (3.6%), and calcium phosphate (3.4%). Only 1 stone was composed of cystine (0.2%). Of all patients, 504 (99.4%) had 1 or several urinary metabolic abnormalities. Hypocitraturia was recorded in 93.9%, high sodium excretion in 58.6%, small urine volume in 45.6%, hyperoxaluria in 31.0%, hypercalciuria in 26.0%, hyperuricosuria in 19.3%, and hyperphosphaturia in 2.8%. Moreover, high sodium excretion was more frequent in men than women (59.2% vs 49.3%, P = .027), whereas hypercalciuria was more common in women (34.5% vs 20.4%, P <.001). High levels of urine sodium (187.7 ± 86.9 vs 179.8 ± 107.7 mmol/24h, P = .038) and phosphate (18.26 ± 8.36 vs 15.69 ± 11.14 mmol/24h, P <.001) were found in men than in women. Infection stones were significantly (P <.004) more common in women. Compared with noninfection stone formers, the occurrence of hypomagnesuria (P = .040) was more common in patients with infection stones. The results of urinary risk factors for stone formation in this study might serve as a basis for design of recurrence prevention. It is of interest to note that some of the demonstrated abnormalities differ from that in reports from other countries.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Citric acid, ACS reagent, ≥99.5%
Sigma-Aldrich
Citric acid, 99%
Sigma-Aldrich
Uric acid, ≥99%, crystalline
Sigma-Aldrich
Sodium, cubes, contains mineral oil, 99.9% trace metals basis
Sigma-Aldrich
Citric acid, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
Sigma-Aldrich
Citric acid, meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)
Supelco
Citric acid, Anhydrous, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hydroxyapatite, reagent grade, powder, synthetic
Sigma-Aldrich
L-Cystine, ≥98% (TLC), crystalline
Sigma-Aldrich
Citric acid, anhydrous, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
L-Cystine, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Cystine, ≥99.7% (TLC)
Sigma-Aldrich
Sodium, ACS reagent, dry
SAFC
L-Cystine
Supelco
Citric acid, analytical standard
Sigma-Aldrich
Citric acid, BioUltra, anhydrous, ≥99.5% (T)
Sigma-Aldrich
Sodium, 99.95% trace metals basis, ingot
Sigma-Aldrich
Citric acid, ≥99.5%, FCC, FG
SAFC
L-Cystine
Sigma-Aldrich
Uric acid, BioXtra, ≥99% (HPLC)
Supelco
L-Cystine, Pharmaceutical Secondary Standard; Certified Reference Material
Calcium oxalate monohydrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium, 25-35 wt % dispersion in paraffin
Sigma-Aldrich
Calcium oxalate, ≥99.9% trace metals basis
Sigma-Aldrich
Calcium phosphate tribasic, 34.0-40.0% Ca basis
Supelco
Citric acid, certified reference material, TraceCERT®
USP
Citric acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
Sigma-Aldrich
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)